X-ray studies of aspartic proteinase-statine inhibitor complexes.

The conformation of a statine-containing renin inhibitor complexed with the aspartic proteinase from the fungus Endothia parasitica (EC 3.4.23.6) has been determined by X-ray diffraction at 2.2-A resolution (R = 0.17). We describe the structure of the complex at high resolution and compare this with a 3.0-A resolution analysis of a bound inhibitor, L-364,099, containing a cyclohexylalanine analogue of statine. The inhibitors bind in extended conformations in the long active-site cleft, and the hydroxyl of the transition-state analogue, statine, interacts strongly with the catalytic aspartates via hydrogen bonds to the essential carboxyl groups. This work provides a detailed structural analysis of the role of statine in peptide inhibitors. It shows conclusively that statine should be considered a dipeptide analogue (occupying P1 to P1') despite lacking the equivalent of a P1' side chain, although other inhibitor residues (especially P2) may compensate by interacting at the unoccupied S1' specificity subsite.

[1]  T. L. Blundell,et al.  Structural evidence for gene duplication in the evolution of the acid proteases , 1978, Nature.

[2]  S. C. Smith,et al.  Synthesis of all the stereoisomers of statine (4-amino-3-hydroxy-6-methylheptanoic acid). Inhibition of pepsin activity by N-carbobenzoxy-L-valyl-L-valyl-statine derived from the four stereoisomers. , 1979, Journal of medicinal chemistry.

[3]  X‐ray data correlation through common reflexions , 1966 .

[4]  D. Rich,et al.  Synthesis of analogues of the carboxyl protease inhibitor pepstatin. Effects of structure on inhibition of pepsin and renin. , 1980, Journal of medicinal chemistry.

[5]  M. James,et al.  Conformational flexibility in the active sites of aspartyl proteinases revealed by a pepstatin fragment binding to penicillopepsin. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[6]  M. L. Connolly.  Analytical molecular surface calculation , 1983 .

[7]  Tom Blundell,et al.  The active site of aspartic proteinases , 1991, FEBS letters.

[8]  T. Aoyagi,et al.  Pepstatin, a new pepsin inhibitor produced by Actinomycetes. , 1970, The Journal of antibiotics.

[9]  A. Rae.  The correlation of zones of X-ray intensity data from common reflexions , 1965 .

[10]  C. Bunn,et al.  An x-ray crystallographic study of the rennin-like enzyme of Endothia parasitica. , 1970, Journal of molecular biology.

[11]  D. Davies,et al.  Three-dimensional structure of the complex of the Rhizopus chinensis carboxyl proteinase and pepstatin at 2.5-A resolution. , 1982, Biochemistry.

[12]  Virander S. Chauhan,et al.  Crystal structure and molecular conformation of the tripeptide, N‐Boc‐L‐Phe‐Dehydro‐Phe‐L‐Val‐OCH3 , 1987, Biopolymers.

[13]  T L Blundell,et al.  On the rational design of renin inhibitors: X-ray studies of aspartic proteinases complexed with transition-state analogues. , 1987, Biochemistry.

[14]  L. Pearl,et al.  The catalytic mechanism of aspartic proteinases , 1987, FEBS letters.

[15]  J. Tang,et al.  Mode of inhibition of acid proteases by pepstatin. , 1976, The Journal of biological chemistry.

[16]  T. Lin,et al.  Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state analogue inhibitors containing a novel analogue of statine. , 1985, Journal of medicinal chemistry.

[17]  D. S. Moss,et al.  Restrain: A restrained least squares refinement program for use in protein crystallography , 1982, Comput. Chem..

[18]  B. L. Sibanda,et al.  Three-dimensional structure, specificity and catalytic mechanism of renin , 1983, Nature.

[19]  J Cooper,et al.  The structure of a synthetic pepsin inhibitor complexed with endothiapepsin. , 1987, European journal of biochemistry.

[20]  L. Polgár.  The mechanism of action of aspartic proteases involves ‘push‐pull’ catalysis , 1987, FEBS letters.

[21]  G. M. Smith,et al.  Electronic distributions within protein phenylalanine aromatic rings are reflected by the three-dimensional oxygen atom environments. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. Levitt,et al.  Conformation of amino acid side-chains in proteins. , 1978, Journal of molecular biology.

[23]  D. Webb,et al.  REDUCTION OF BLOOD PRESSURE IN MAN WITH H-142, A POTENT NEW RENIN INHIBITOR , 1983, The Lancet.

[24]  E. Padlan,et al.  Binding of a reduced peptide inhibitor to the aspartic proteinase from Rhizopus chinensis: implications for a mechanism of action. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[25]  F. S. Mathews,et al.  A semi-empirical method of absorption correction , 1968 .

[26]  M. James,et al.  Stereochemical analysis of peptide bond hydrolysis catalyzed by the aspartic proteinase penicillopepsin. , 1985, Biochemistry.

[27]  Synthesis of dideoxy-pepstatin. Mechanism of inhibition of porcine pepsin. , 1977, Biochemical and biophysical research communications.

[28]  R. Workman,et al.  Pepsin inhibition by a high specific activity radioiodinated derivative of pepstatin. , 1979, Archives of biochemistry and biophysics.

[29]  T. A. Jones,et al.  A graphics model building and refinement system for macromolecules , 1978 .

[30]  D. Rich,et al.  Synthesis of analogues of the carboxyl protease inhibitor pepstatin. Effect of structure in subsite P3 on inhibition of pepsin. , 1982, Journal of medicinal chemistry.

[31]  David S. Moss,et al.  Restrained structure-factor least-squares refinement of protein structures using a vector processing computer , 1985 .

[32]  B. L. Sibanda,et al.  Computer graphics modelling of human renin , 1984, FEBS letters.

[33]  D. Veber,et al.  Novel renin inhibitors containing the amino acid statine , 1983, Nature.

[34]  B. Dunn,et al.  A systematic series of synthetic chromophoric substrates for aspartic proteinases. , 1986, The Biochemical journal.

[35]  B. Dunn,et al.  The pH dependence of the hydrolysis of chromogenic substrates of the type, Lys-Pro-Xaa-Yaa-Phe-(NO2)Phe-Arg-Leu, by selected aspartic proteinases: evidence for specific interactions in subsites S3 and S2. , 1987, Biochimica et biophysica acta.

[36]  Frederic M. Richards,et al.  Packing of α-helices: Geometrical constraints and contact areas☆ , 1978 .

[37]  J D Baxter,et al.  Structure of recombinant human renin, a target for cardiovascular-active drugs, at 2.5 A resolution. , 1989, Science.

[38]  T. L. Blundell,et al.  High resolution X-ray analyses of renin inhibitor-aspartic proteinase complexes , 1987, Nature.

[39]  R. Read.  Improved Fourier Coefficients for Maps Using Phases from Partial Structures with Errors , 1986 .

[40]  M. James,et al.  Molecular structure of an aspartic proteinase zymogen, porcine pepsinogen, at 1.8 Å resolution , 1986, Nature.

[41]  A. Berger,et al.  Mapping the active site of papain with the aid of peptide substrates and inhibitors. , 1970, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[42]  F. Salituro,et al.  Inhibition of aspartic proteinases by peptides containing lysine and ornithine side-chain analogues of statine. , 1987, Journal of medicinal chemistry.